arrow
E

Elena Vigliar

department of public health
H指数:34
被引数:3,147

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Design and analytical validation of Nexthyro 2.0, a custom next-generation sequencing panel integrating DNA mutation profiling and RNA fusion detection for routine thyroid pathology specimens

Nexthyro 2.0的设计与分析验证,一种定制化下一代测序panel,整合DNA突变分型和RNA融合检测,用于常规甲状腺病理标本

2026-08-310
OAAI
Breast cancer risk in female survivors of Hodgkin lymphoma after exposure to non-pegylated liposomal doxorubicin at young adult and adult age: the first real-life series from Southern Italy cancer centers

霍奇金淋巴瘤女性幸存者在年轻成年和成年时期接触非聚乙二醇化脂质体多柔比星后的乳腺癌风险:来自意大利南部癌症中心的首个真实世界病例系列

2026-07-160
OA
Analytical reliability of cell-free DNA from fine-needle aspiration rinses for BRAF and NRAS testing in metastatic melanoma

从细针抽吸冲洗液中获取的无细胞DNA在转移性黑素瘤中检测BRAF和NRAS的分析可靠性

2026-05-011
PRE
FKBP5 isoforms shape immune pathways related to tumor tolerance

FKBP5异构体塑造与肿瘤耐受相关的免疫通路

2026-03-260
OAAI
Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers

Brentuximab Vedotin联合多柔比星、长春碱和达卡巴嗪,用于18-59岁未经治疗晚期经典型霍奇金淋巴瘤患者:来自意大利南部癌症中心的最大真实世界系列研究

2025-11-010
OAAI
WHOverlap Multicentre Study: Dissecting the Insufficient/Inadequate/Non-Diagnostic Category and Its Overlap with the Benign Category in the WHO Reporting System for Lung Cytopathology

WHOverlap多中心研究:解析WHO肺癌细胞病理学报告系统中的不足/不充分/非诊断类别及其与良性类别的重叠情况

2025-10-010
PRE
Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long-term efficacy results of a retrospective multicentre study

贝antasine超充电联合brentuximab vedotin作为经典霍奇金淋巴瘤患者在≤60岁患者中,在完成两个周期adriamycin-bleomycin-vinblastine-dacarbazine治疗后未达到完全代谢缓解后的早期挽救性治疗:一项回顾性多中心研究的长期疗效结果

2025-04-020
OAAI
Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi-Center Real-Life Study
2024-11-170
OAAI
RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy
2024-10-010
OA
Ultrasonography-guided core-needle biopsy of lymphadenopathies suspected of lymphoma: Analysis on diagnostic efficacy and safety of 1000 front-line biopsies in a multicenter Italian study
2023-07-066
OAAI
Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21
2023-02-151
OAAI